Menlo Therapeutics, which is developing treatments for moderate to severe skin itch and chronic cough, raised $119 million by offering 7 million shares at $17, the high end of the range of $16 to $17. Menlo Therapeutics plans to list on the Nasdaq under the symbol MNLO. Jefferies, Piper Jaffray and Guggenheim Securities acted as lead managers on the deal.
